Search
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalsynthesized without loss of proper bond formation or structural elements. … [A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.
Categories: Analgesics, Non-Narcotic, Calcium Channels, N-TypeColfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawn[A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990. … Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome.
Methyl aminolevulinate
go.drugbank.com/drugs/DB00992ApprovedInvestigationalMethyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.
Categories: Sensitizers Used in Photodynamic/radiation TherapyUrea C-14
go.drugbank.com/drugs/DB09513ApprovedInvestigationalRadiolabelled urea is available in two forms as 13C and 14C. … The Urea Breath Test is based on the ability of the H. pylori enzyme urease to cleave urea into ammonia and carbon dioxide.
Cyproheptadine
go.drugbank.com/drugs/DB00434ApprovedInvestigational[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.
Synonyms: 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidineSelpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigational[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated
Suzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigational[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain
Categories: Analgesics, Non-NarcoticDabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]
Pilaralisib
go.drugbank.com/drugs/DB11772InvestigationalPilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). … Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnOn August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver … New Zealand and Canada have also followed suit in recalling the drug.
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal